Trial Profile
An Open Label, Randomised, Three-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs BI-54903/olodaterol (Primary) ; BI 54903; Olodaterol
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 27 Aug 2014 New trial record